Spots Global Cancer Trial Database for Use of Tamoxifen in Systemic Mastocytosis

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Use of Tamoxifen in Systemic Mastocytosis

Official Title: Treatment of Systemic Mastocytosis With Tamoxifen

Study ID: NCT01334996

Conditions

Systemic Mastocytosis

Interventions

Study Description

Brief Summary: In this study, the investigators will determine the utility of Tamoxifen, a non-cytotoxic agent, to improve quality of life, biochemical parameters, and bone marrow involvement in systemic mastocytosis patients having 1) up to 40% bone marrow infiltration by mast cells and/or 2) mediator-release symptoms which are not controlled by tolerated doses of standard "non-cytotoxic" medications regardless of the percentage bone marrow involvement by mastocytosis. The dose of Tamoxifen will be 40 mg/day and the duration of treatment will be for one year. Patients currently taking interferon alfa, imatinib mesylate, or cladribine will be excluded until these medications have been stopped.

Detailed Description: Not desired